CHEK2 and cancer: The median age for cancer diagnosis across the BRCA1/2 mutation carriers was 46 years, in the CHEK2 group it was 42.5 years, 44.8 years for ATM, 48.6 years for PALB2, 44 years for MUTYH, and 45.6 years for BLM.